Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07594015 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

StatusRecruiting
PhasePhase 2
Started2026-08-06
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jun 1, 2031 → Sep 1, 2031
See other at-risk trials from University of Miami

Amendment history

2026-08-24
Study Status v2
Primary completion date2031-09-01→2031-08-31
Completion date2031-09-01→2031-08-31
Start dateestimated 2026-09-01→confirmed 2026-08-06
2026-07-09
Study Status v1
Primary completion pushed: 2031-06-01 → 2031-09-01
Completion pushed: 2031-06-01 → 2031-09-01
Start date2026-06-01→2026-09-01
2026-05-11
Original filing
The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.
Trial Details
NCT Number NCT07594015
Lead Sponsor University of Miami
Conditions Recurrent Endometrial Cancer
Enrollment 46 participants
Start Date 2026-08-06
Primary Completion 2031-08-31 (estimated)
Study Completion 2031-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-24